Study unravels mystery of cancer-fueling enzyme, which could lead to new therapies
For organs to develop, grow and regenerate, cells must proliferate. But when that process goes awry, leading to uncontrolled ...
Clinical Trials Arena on MSN2d
Ractigen’s RAG-01 shows potential in treating non-muscle invasive bladder cancer
The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...
Vincerx Pharma (VINC) Expected to Announce Earnings on Friday
Vincerx Pharma (NASDAQ:VINC – Get Free Report) is projected to release its earnings data before the market opens on Friday, ...
Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Down 64.1% in March
Vincerx Pharma, Inc. (NASDAQ:VINC – Get Free Report) was the recipient of a significant decrease in short interest during the ...
BioWorld11d
CDK12/cyclin K degradation inducers disclosed in Proxygen patent
Proxygen GmbH has divulged molecular glue degraders comprising a cullin-ring E3 ligase (CRL)-binding moiety acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degradation inducers reported to be ...
GlobalData on MSN3d
Sermonix and Regor to enhance breast cancer treatment options
The partnership is expected to yield treatments that demonstrate efficacy and offer improved quality of life and tolerability ...
Pharmabiz16d
Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial
Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...
MPR10d
Vepdegestrant Beneficial in ER+/HER2- Breast Cancer With ESR1 Mutations
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.